AU2020366354A1 - Methods of treating cancer with a sting agonist - Google Patents

Methods of treating cancer with a sting agonist Download PDF

Info

Publication number
AU2020366354A1
AU2020366354A1 AU2020366354A AU2020366354A AU2020366354A1 AU 2020366354 A1 AU2020366354 A1 AU 2020366354A1 AU 2020366354 A AU2020366354 A AU 2020366354A AU 2020366354 A AU2020366354 A AU 2020366354A AU 2020366354 A1 AU2020366354 A1 AU 2020366354A1
Authority
AU
Australia
Prior art keywords
compound
administered
dose
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020366354A
Other languages
English (en)
Inventor
Zhijian Chen
Lijun Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Immunesensor Therapeutics Inc
Original Assignee
University of Texas System
University of Texas at Austin
Immunesensor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, Immunesensor Therapeutics Inc filed Critical University of Texas System
Publication of AU2020366354A1 publication Critical patent/AU2020366354A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020366354A 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist Abandoned AU2020366354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914881P 2019-10-14 2019-10-14
US62/914,881 2019-10-14
PCT/US2020/055633 WO2021076666A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Publications (1)

Publication Number Publication Date
AU2020366354A1 true AU2020366354A1 (en) 2022-03-17

Family

ID=73060121

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020366354A Abandoned AU2020366354A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Country Status (7)

Country Link
US (1) US20230270773A1 (https=)
EP (1) EP4045059A1 (https=)
JP (1) JP2023500045A (https=)
CN (1) CN114929241A (https=)
AU (1) AU2020366354A1 (https=)
CA (1) CA3157849A1 (https=)
WO (1) WO2021076666A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014110A (es) * 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
AU2017378782A1 (en) * 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment

Also Published As

Publication number Publication date
WO2021076666A1 (en) 2021-04-22
EP4045059A1 (en) 2022-08-24
JP2023500045A (ja) 2023-01-04
CN114929241A (zh) 2022-08-19
CA3157849A1 (en) 2021-04-22
US20230270773A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
KR102446673B1 (ko) 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
JP2026503515A (ja) 非ホジキンリンパ腫治療用医薬組成物及びその使用
KR20240130081A (ko) 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
US20230270773A1 (en) Methods of treating cancer with a sting agonist
US20230121320A1 (en) Sting agonist combination treatments with cytokines
JP2022551672A (ja) 乳癌治療法
HK40076423A (en) Methods of treating cancer with a sting agonist
KR20240046527A (ko) 암치료를 위한 신규 경구용 약학적 조성물
HK40087098A (zh) Sting激动剂与免疫检查点抑制剂的联合治疗
US20210315898A1 (en) Combination therapy for treating cancer
US20220251203A1 (en) Use of anti-pd-1 antibody in combination with famitinib in preparation of drug for treating tumors
Eatmann et al. Potential use of thalidomide in glioblastoma treatment: an updated brief overview. Metabolites. 2023; 13: 543
EP4506015A1 (en) Combination of a mps1 inhibitor and an antibody drug conjugate
WO2021224381A1 (en) Combination therapy for treating cancer
Mohamed et al. Potential use of thalidomide in glioblastoma treatment: an updated brief overview
Yang et al. EXTH-77. POLIO VIROTHERAPY OF MURINE BRAIN TUMORS INDUCES MICROGLIA PROLIFERATION AND INFLAMMATION THAT IS POTENTIATED BY IMMUNE CHECKPOINT BLOCKADE
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent